LivaNova (NASDAQ:LIVN) Price Target Raised to $70.00

LivaNova (NASDAQ:LIVN) had its target price increased by analysts at Stifel Nicolaus from $65.00 to $70.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 8.29% from the stock’s previous close.

A number of other research firms have also issued reports on LIVN. KeyCorp assumed coverage on LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. Robert W. Baird set a $75.00 price target on shares of LivaNova in a research note on Tuesday, December 16th. The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, Mizuho upped their price objective on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and a consensus target price of $66.88.

LivaNova Stock Up 0.8%

LivaNova stock opened at $64.64 on Wednesday. The firm has a market capitalization of $3.53 billion, a P/E ratio of -15.99 and a beta of 0.97. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. LivaNova has a twelve month low of $32.48 and a twelve month high of $65.57. The stock’s fifty day simple moving average is $59.40 and its 200-day simple moving average is $53.74.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Primecap Management Co. CA raised its position in shares of LivaNova by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after purchasing an additional 32,942 shares during the last quarter. Millennium Management LLC grew its holdings in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after buying an additional 544,033 shares during the last quarter. Artisan Partners Limited Partnership increased its position in LivaNova by 94.5% during the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after buying an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after acquiring an additional 1,067,349 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of LivaNova by 30.5% in the second quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock valued at $92,201,000 after acquiring an additional 478,525 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.